TNFRSF9 and neoplasm: Murine models support the use of 4-1BB agonists in combination with anti-PD-1 ICB in promoting effective anti-tumour immune responses, demonstrating an elevated CD8+/Treg ratio and increased activity of tumour-specific cytotoxic T lymphocytes and enrichment of genes including IFN-γ, and EOMES [92].